$VOGX

Vogenx, Inc.

Vogenx is a clinical-stage drug development company focused on therapies for metabolic conditions, including post-bariatric hypoglycemia and gastroparesis. Its drug candidates include mizagliflozin and VGX-2857, as well as VGX-001, a human monoclonal antibody being developed to treat type 1 diabetes. The company is based in Raleigh, North Carolina.

No enriched coverage for $VOGX in the last 7 days.

No SEC Form 4 filings for $VOGX in the last 30 days.

See all $VOGX insider activity →

Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights

Vogenx, Inc. (VOGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights Advances PBH Development Program Following August 2026 Initial Public Offering Strengthens Balance Sheet with $82.1 Million in Total Cash, Cash Equivalents, and Marketable Securities RALEIGH,

A drug study for low blood sugar after weight-loss surgery has begun

Vogenx, Inc. (NASDAQ:VOGX) reported Q3 2026 results, highlighting $82.1M in cash, $1.1M in R&D expenses, and a net loss of $4.9M. The company initiated a Phase 2b study for mizagliflozin in post-bariatric hypoglycemia and plans a Phase 2 study for gastroparesis. Leadership updates include new board and management appointments.

VOGX sentiment & insider activity

Recent VOGX coverage spans corporate actions, earnings and financial news.

What's driving VOGX

  • Vogenx reported a Q3 GAAP loss of $0.47 per share, missing estimates by $0.40. The company had $82.1 million in cash and equivalents at the end of September 2026, up from $601,000 at the end of 2025, due to its August 2026 IPO.

    tokenpost.com · Nov 8, 2026

  • Earnings release shows higher loss but strong cash position; market may view cash raise positively but loss pressure could weigh.

    SEC EDGAR 8-K · Nov 6, 2026

  • The trial start adds clinical‑development risk and upside potential for Vogenx.

    stocktitan.net · Nov 6, 2026

  • Trial initiation is a meaningful clinical development step that can improve perceived probability of future efficacy and regulatory progress, but it is not efficacy data yet.

    stocktitan.net · Oct 15, 2026

  • The executive transition may cause short‑term stock pressure as investors reassess board composition and leadership continuity.

    tradingview.com · Oct 9, 2026

AlphAI scores every news story that mentions VOGX with an AI model for sentiment and relevance, and aggregates insider trades from Vogenx, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $VOGX

Score

Blood-sugar drops after weight-loss surgery have no FDA-approved treatment. Vogenx starts a trial.

Vogenx (NASDAQ:VOGX) initiated a Phase 2b trial for mizagliflozin, a treatment for post-bariatric hypoglycemia (PBH), a condition with no FDA-approved therapies. The EMERGE trial will enroll 36 adults, testing 5 mg and 10 mg doses against placebo. Mizagliflozin aims to reduce hypoglycemic events by delaying glucose absorption in the small intestine. Vogenx's CEO and CSO highlighted the trial's significance and the drug's potential.

Vogenx's Richard Gorman resigns from board to become Chief Commercial Officer

Vogenx appointed Richard Gorman as Chief Commercial Officer, effective October 12, 2026. Gorman resigned from the board and all committees. The company stated the change was not due to any disagreement. No replacement was disclosed. According to the SEC filing, this change is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

$VOGXLowExec change

Vogenx, Inc. (VOGX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Vogenx, Inc. (VOGX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 VOGENX, INC. 3901 Barrett Drive, Suite 300 | Raleigh, North Carolina 27609 | Nasdaq: VOGX FOR IMMEDIATE RELEASE Vogenx Appoints Board Member Richard Gorman as Chief Commercial Officer Thirty-year biopharmaceutical commercial leader transitions from the Board of Direc

$VOGXLowExec change· appointed

Vogenx, Inc. (VOGX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Vogenx, Inc. (VOGX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 VOGENX, INC. 3901 Barrett Drive, Suite 300 | Raleigh, North Carolina 27609 | Nasdaq: VOGX FOR IMMEDIATE RELEASE Vogenx Appoints Ken Toombs to Board of Directors Former Chief Executive Officer of PA Consulting brings three decades of global professional services and l

William Wilkison Net Worth (2026)

William Wilkison reportedly owns 1.8 million shares of Vanguard Extended Duration Treasury ETF (VOGX), valued at $56.6 million. No insider trades have been filed by Wilkison in VOGX since 2021, according to SEC filings.

Vogenx Inc - Common Stock (VOGX)

Vogenx, Inc. (VOGX) closed its initial public offering of 6.25 million shares at $13.00 per share, raising approximately $81.3 million before expenses. The biopharmaceutical company focuses on treatments for metabolic dysfunctions, including post-bariatric hypoglycemia and gastroparesis.

Related tickers